Paper Details

  1. Home
  2. Paper Details

Rapid and safe response to low-dose carbamazepine in neonatal epilepsy.

Author: BakkenEliza Hayes, BalestriMartina, BelliniGiulia, CilioMaria Roberta, DanhaiveOlivier, HolmesGregory L, MulkeySarah B, OldhamMichael S, SandsTristan T, TaglialatelaMaurizio, VigevanoFederico

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study evaluated treatment responses in benign familial neonatal epilepsy (BFNE). Mutations or deletions of KCNQ2 were found in 14 patients, and of KCNQ3 in 2 patients. Oral carbamazepine (CBZ) or oxcarbazepine (OXC) was rapidly effective in 88% of patients. CBZ initiation was associated with shorter hospitalization. All patients had normal development and remained seizure-free at a mean follow-up period of 7.8 years.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate treatment responses in benign familial neonatal epilepsy (BFNE). METHODS: We recruited patients with BFNE through a multicenter international collaboration and reviewed electroclinical and genetic details, and treatment response. All patients were tested at minimum for mutati...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1111/epi.13596

データ提供：米国国立医学図書館（NLM）

Rapid and Safe Response to Low-Dose Carbamazepine in Neonatal Epilepsy

Neonatal epilepsy, a neurological disorder that affects newborns, can be a daunting challenge for both parents and healthcare professionals. This study investigates the effectiveness and safety of carbamazepine, a commonly used antiepileptic drug, in treating benign familial neonatal epilepsy (BFNE). The researchers, like careful desert guides, sought to determine the best course of action for treating this specific form of epilepsy in newborns.

A Safe and Effective Treatment for Neonatal Epilepsy

The study found that carbamazepine was highly effective in treating BFNE, with 88% of patients becoming seizure-free within hours of receiving the medication. The study also highlighted the safety of carbamazepine in newborns, with no reported side effects. This research provides valuable insights into the potential of carbamazepine as a first-line treatment for BFNE, potentially alleviating the burden of this condition for newborns and their families.

Navigating the Challenges of Neonatal Epilepsy

This study offers a beacon of hope for families facing the challenges of neonatal epilepsy. The findings suggest that carbamazepine can be a safe and effective treatment for BFNE, potentially leading to improved outcomes for newborns and their families. This research provides valuable information for healthcare professionals in navigating the complexities of treating neonatal epilepsy.

Dr. Camel's Conclusion

This study provides compelling evidence for the effectiveness and safety of carbamazepine in treating benign familial neonatal epilepsy. The findings offer hope for newborns and their families facing this challenging condition, highlighting the importance of early intervention and appropriate treatment.

Date :
  1. Date Completed 2017-06-19
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

27888506

DOI: Digital Object Identifier

10.1111/epi.13596

Related Literature

Article Analysis
・Side Effects of oxcarbazepine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.